• +1-646-491-9876
    • +91-20-67278686

    Search

    Diabetic Gastroparesis - Pipeline Review, H1 2017

    Diabetic Gastroparesis - Pipeline Review, H1 2017

    • Report Code ID: RW0001709490
    • Category Pharmaceuticals
    • No. of Pages 57
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Diabetic Gastroparesis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2017, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape.

    Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts of the body, including the vagus nerve, which controls contractions of the stomach during digestion. Spasms, abdominal pain, feelings of fullness after a small amount of food, and other symptoms such as nausea and vomiting, reflux, heartburn, and bloating are often experienced with gastroparesis. Loss of appetite and reduced absorption of nutrients may also be experienced. Gastroparesis can lead to weight loss and malnutrition.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis (Gastrointestinal) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Diabetic Gastroparesis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 3, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Diabetic Gastroparesis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis (Gastrointestinal) .
    - The pipeline guide reviews pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Diabetic Gastroparesis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Diabetic Gastroparesis (Gastrointestinal) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Diabetic Gastroparesis (Gastrointestinal) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Diabetic Gastroparesis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Diabetic Gastroparesis - Overview
    Diabetic Gastroparesis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Diabetic Gastroparesis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Diabetic Gastroparesis - Companies Involved in Therapeutics Development
    Cempra Inc
    Evoke Pharma Inc
    GlaxoSmithKline Plc
    Motus Therapeutics Inc
    Shire Plc
    Theravance Biopharma Inc
    Diabetic Gastroparesis - Drug Profiles
    camicinal - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CEM-031 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ETX-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ETX-301 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    metoclopramide hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    prucalopride succinate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    relamorelin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    renzapride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Activate nNOS for Diabetic Gastroparesis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    velusetrag hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Diabetic Gastroparesis - Dormant Projects
    Diabetic Gastroparesis - Discontinued Products
    Diabetic Gastroparesis - Product Development Milestones
    Featured News & Press Releases
    Jan 04, 2017: Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial
    Dec 15, 2016: Evoke Receives Positive NDA Submission Guidance from US FDA for Gimoti
    Dec 06, 2016: Theravance Biopharma Receives FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis
    Sep 07, 2016: Evoke Pharma Announces Positive Non-Clinical Pre-NDA Meeting with FDA for Gimoti
    Jul 26, 2016: Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001
    Jul 18, 2016: Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial
    Jul 07, 2016: Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement
    Jun 01, 2016: Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
    May 24, 2016: Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016
    May 19, 2016: Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001
    May 03, 2016: Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001
    Apr 25, 2016: Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
    Apr 04, 2016: Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis
    Mar 03, 2016: Evoke Accelerates New Drug Application Process by Engaging Regulatory Experts
    Mar 01, 2016: Evoke Nears Completion of Phase 3 Clinical Trial Enrollment and Secures Extension to Credit Facility
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Diabetic Gastroparesis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Diabetic Gastroparesis - Pipeline by Cempra Inc, H1 2017
    Diabetic Gastroparesis - Pipeline by Evoke Pharma Inc, H1 2017
    Diabetic Gastroparesis - Pipeline by GlaxoSmithKline Plc, H1 2017
    Diabetic Gastroparesis - Pipeline by Motus Therapeutics Inc, H1 2017
    Diabetic Gastroparesis - Pipeline by Shire Plc, H1 2017
    Diabetic Gastroparesis - Pipeline by Theravance Biopharma Inc, H1 2017
    Diabetic Gastroparesis - Dormant Projects, H1 2017
    Diabetic Gastroparesis - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Diabetic Gastroparesis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Cempra Inc
    Evoke Pharma Inc
    GlaxoSmithKline Plc
    Motus Therapeutics Inc
    Shire Plc
    Theravance Biopharma Inc

    Request for Sample

    Report Url https://www.reportsweb.com//diabetic-gastroparesis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//diabetic-gastroparesis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//diabetic-gastroparesis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments